药明康德(603259.SH)发预增,预计2025年度归母净利润约191.51亿元,同比增约102.65%
智通财经网·2026-01-12 09:37

Core Viewpoint - WuXi AppTec (603259.SH) expects to achieve a net profit attributable to shareholders of approximately RMB 19.151 billion in 2025, representing a year-on-year growth of about 102.65% [1] Group 1: Business Model and Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - It is committed to meeting customer demands for empowerment and is continuously expanding new capabilities and building new production capacity [1] - The company aims to optimize production processes and improve operational efficiency to drive steady business growth [1] Group 2: Commitment to Clients and Market - WuXi AppTec is dedicated to empowering clients efficiently and aims to bring more new and effective drugs to patients worldwide [1]

WuXi AppTec-药明康德(603259.SH)发预增,预计2025年度归母净利润约191.51亿元,同比增约102.65% - Reportify